INTRODUCTION
Radiotherapy is one of the established local-regional treatments for head and neck cancer. Linear accelerator based fractionated external-beam radiotherapy with or without concurrent chemotherapy is generally considered as a standard treatment method. 1, 2) However, close proximity of several critical organs such as optic pathways, brain stem, and spinal cord sometimes limit high dose delivery from conventional radiotherapy technique. Recently, development of the image guided stereotactic radiotherapy devices make it possible to deliver highly conformal radiotherapy for head and neck cancers, as is the case in central nervous system tumors. 3, 4) In general, for mainly practical and economical reasons, these devices are not suitable for long-course conventionally fractionated radiotherapy. Although effects of normal-tissue sparing can allow the use of hypofractionation theoretically, necessity of therapeutic and prophylactic nodal irradiation make it difficult to use large dose per fractionation for relatively large target volume in the head and neck region. Thus, at present, fractionated stereotactic radiotherapy is mainly used for salvage treatment of locally recurrent tumors. [4] [5] [6] [7] The CyberKnife system was specifically developed to perform frameless stereotactic radiosurgery for intracranial lesions, 3) and the technique can now be applied to deliver conformal doses of radiation to tumors throughout the head and neck region. In the present study, we report our initial experience of using CyberKnife system for a boost treatment for tumors in the head and neck area.
MATERIALS AND METHODS

Patient characteristics
From March 2008 to August 2009, 10 patients were treated with image guided stereotactic radiotherapy (SRT) boost using CyberKnife system (CyberKnife II, Accuray Inc., Sunnyvale, CA) for head and neck lesions. Patient charac-teristics were shown in Table 1 . Patient's age ranged from 35 to 80. Male to female ratio was 8:2. Treatment sites were the external auditory canal in two, the nasopharynx in one, the oropharynx in three, the nasal cavity in one, the maxillary sinus in two, oligometastatic cervical lymph node from the esophageal cancer in one. The UICC-TNM (2002) classification was applied for all patients other than those with cancer in the external auditory canal, for whom the tumor staging system devised by Stell and McCormick was used. 8) All patients in this study underwent preceding conventional radiotherapy for a curative intent using linear accelerator with suitable energies at the neighboring university hospital before SRT boost. Total dose of the conventional radiotherapy ranged from 40 to 60 Gy, with a fractional daily isocenter dose of 2 Gy. Planning target volumes of initial conventional treatment included prophylactic nodal area in patients with nasopharyngeal cancer, oropharyngeal cancer, and metastatic cervical lymph node, but for patients with maxillary sinus and external auditory canal cancer. For all patients, three-dimensional (3D) treatment planning using CT-simulator (AcQSIM, PQ2000, Picker Inc) with 3D treatment planning system (Xio ver. 4.40, CMS Japan Inc.) was performed. No intensity-modulated radiotherapy technique *: estimated from data of previous three-dimensional treatment planning SRT: stereotactic radiation therapy, RT: radiation therapy was used for any of the patients. Time from the preceding radiotherapy to boost SRT ranged from one to three days. Reasons to use SRT boost, more than one reason for some patients, were as follows: presence of tumor adjacent to the optic pathway in four, the brain stem in one, the mandible in three, a planning target volume was limited by former radiotherapy fields for other malignancies in two, and a tumor was localized in the external auditory canal area in two. Patients with T3-4 tumor and oligometastatic cervical lymph node received cisplatin-based chemotherapy concurrently with preceding conventional radiotherapy. Written informed consent was obtained from all patients. The study was in accordance with the Declaration of Helsinki (2001).
SRT boost by CyberKnife treatment system
The Cyberknife SRT system is composed of 6-MV Xband linear accelerator mounted on a fully articulated robotic arm. Patients were immobilized non-invasively using a custom-made thermoplastic mask (E-frame, Qualita, Inc. Japan) in a supine position. During treatment, a pair of orthogonal X-ray cameras provided real-time images of patients' anatomy. In a patient with metastatic cervical lymph node, cervical spines were used for tracking anatomy. Remaining 9 patients were treated under skull-tracking system. All patients underwent a pre-treatment contrast-enhanced thinslice (1.0 mm) CT from the top of the skull to the thoracic inlet including the lesion of interest. CT images were fused with T1-weighted MRI with gadolinium to determine more precisely the extent of the lesions. However, because of heterogeneity in the anatomical complexity, it was necessary to determine individually the clinical target volume (CTV) margin around the gross tumor volume (GTV) with a 0-to 5-mm. In a patient with T1N0 external auditory canal cancer, it was impossible to delineate GTV on diagnostic images.
Fig. 1.
A 72-year-old patient with oropharyngeal cancer. After conventional external beam radiotherapy of 50 Gy, because of close proximity of the primary tumor to the mandible, stereotactic radiotherapy boost using CyberKnife system was chosen for this patient. Isodose lines on axial, coronal, and sagittal images show the small-volume high dose area in the mandible.
For this patient, the entire external auditory canal was defined as CTV. As with other reported series, no additional margin was added for the planning target volume. [5] [6] [7] Critical organ structures were contoured for possible exclusion from treatment. Inverse planning was used to determine the dose to the target volume while minimizing the dose to surrounding normal tissues. Non-isocentric conformal beams were utilized for all patients. Dose was prescribed to cover at least 95% of the CTV received intended dose, resulting the prescribed isodose line being 59 to 79%. Dose and fractionation scheme was individualized, and prescribed dose ranged from 9 Gy in three fracions to 16 Gy in 4 fractions. During each treatment session, X-ray images are acquired frequently and compared with digitally reconstructed radiographs, thus tracking target volume movements throughout the procedure guiding the radiation beam with less than 1-millimeter precision. The SRT boost treatment parameters were shown in Table 2 .
Accuracy test of the CyberKnife system
The total system accuracy of the CyberKnife is defined as the translational deviation of a spherical dose distribution delivered to a phantom including the error compiled across the entire treatment procedures such as CT acquisition, treatment planning, and delivery of radiation therapy. For treatment of head and neck lesions, it is determined using an anthropomorphic head-and-neck phantom, which contains an insert for an orthogonal set of radiochromic films. The procedure has recently been described in detail.
9) The total system accuracy was measured on a monthly basis.
RESULTS
Dose to critical organs by SRT boost
The maximum and minimum doses to critical organs were summarized in Table 3 . Doses to critical organs delivered by previous conventional radiotherapy were estimated by reviewing treatment planning of each patient. Dose to the Fig. 2 . A 40-year-old man with nasopharyngeal cancer invading broadly the bony skull base (T3N0M0). He received stereotactic radiotherapy boost intending to spare the optic chiasm and the brain stem after the conventional radiotherapy of 50 Gy. There was a small high dose area at the ventral portion of the brain stem. Although the highest dose in the brain stem was 15 Gy, majority of the high dose area in the brain stem received doses in the range of 8.1 to 10.9 Gy (corresponding to 30-40% dose of the maximum dose) in 4 fractions. Since the clivus was entirely replaced by the tumor, treatment plan for this patient had not improved by repeated inverse planning. This plan was considered to be clinically acceptable. optic pathway was concerned in four patients. The maximum dose in three of four patients is about 3 Gy, whereas 9.6 Gy in four fractions for one patient with maxillary sinus cancer. However, hot spot in that patient was situated on posterior portion of the ipsilateral optic nerve, and optic chiasm was successfully spared by SRT boost technique. One of three patients with opopharyngeal cancer received high dose to the mandible. Because the tongue base cancer in that patient attached to the mandible, it was impossible to spare completely the ipsilateral mandible from high dose exposure from SRT boost. However, only a small portion of the ipsilateral mandible received high dose whereas majority of the bone can be spared by using non-isocentric conformal beams, resulting this plan to be considered as clinically acceptable in this setting (Fig. 1) . A patient with nasopharyngeal cancer which invaded broadly the bony skull base received SRT boost intending to spare the optic chiasm and the brain stem after the preceding conventional radiotherapy of 50 Gy. Although dose to the optic pathway could be reduced within acceptable range, there was a small but apparent hot spot at the ventral portion of the brain stem (Fig. 2) . Since the clivus was entirely replaced by the tumor, treatment plan for this patient had not remarkably improved by repeated inverse planning. The highest dose in the brain stem was 15 Gy, however, majority of the brain stem received less than 10.9 Gy, corresponding to 40% dose of the maximum dose, in 4 fractions. Thus, this plan was considered to be clinically acceptable.
Responses, patterns of failure, and treatment sequels
Patients were followed up at 1 to 3 months after CyberKnife SRT boost. The follow-up ranged from 6 to 24 months with a median of 16 months. The tumor responses were evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Six patients showed complete tumor response as assessed by imaging studies, biopsy, clinical examination, or a combination of these procedures. Remaining four patients had partial tumor response. Local progression was observed in three patients at 5, 12, and 13 months with a dose profile (conventional radiotherapy dose plus SRT boost dose) of 50 Gy plus 15 Gy in 4 fractions, 50 Gy plus 14 Gy in 4 fractions, and 40 Gy plus 16 Gy in 4 fractions, respectively. One patient experienced distant metastasis at 6 months after treatment. All three local progressions were within the CTV of SRT boost. Adverse effects were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Of six patients who received cisplatin-based chemotherapy concurrently with preceding conventional radiotherapy, one patient experienced acute grade 2 esophagitis and three patients developed acute grade 3 oral cavity-pharyngeal mucositis. Two patients with external auditory canal cancer developed grade 2 acute otitis. No grade 3 or worse acute toxicity directly attributable to SRT boost component could be observed.
Although a median follow-up period was too short to evaluate late adverse events, no grade 3 or worse late toxicity could be observed in surviving patients. Above-mentioned two patients who had received high dose, but small volume, to risk organs are still closely followed up for late adverse effects of radiotherapy.
DISCUSSION
The CyberKnife is a frameless stereotactic radiotherapy system consisting of a 6 MV X-band linear accelerator mounted on a flexible robotic arm. The flexibility for nonisocentric beam delivery allows optimal dose conformity without compromising dose homogeneity despite irregularshaped tumors, either in single or multiple fractions. This system includes two orthogonally situated kilovoltage X-ray imaging sources and corresponding amorphous silicon detectors working with CT images obtained before radiation, which enable tracking real-time target motion to a high degree of precision. Non-invasive frameless system makes it easy to perform fractionated SRT. Targeting accuracy is reported to be less than 1 mm. 10, 11) Originally, the CyberKnife system was specifically developed to perform frameless stereotactic radiosurgery for intracranial lesions, 3) and the technique can now be applied to deliver high doses of radiation to tumors anywhere in the body with greater precision as compared with other more conventional techniques. The system allows conformal treatment to tumors throughout the head and neck region. However, the CyberKnife system is not suitable for long-course conventionally fractionated radiotherapy. In addition, although effects of normal-tissue sparing can allow the use of hypofractionation for some tumors in the central nervous system, necessity of therapeutic and prophylactic nodal irradiation makes it difficult to use large dose per fractionation for relatively large target volume. Thus, at present, fractionated SRT using the CyberKnife is mainly utilized in reirradiation for patients with recurrent head and neck cancer after definitive radiation therapy. [4] [5] [6] [7] Efficacy and toxicity in the setting of re-irradiation for recurrent tumor are beyond the scope of the present study. Few studies have investigated feasibility and clinical outcome of CyberKnife SRT boost for head and neck cancer. A study by Le et al. presented excellent local control, 100% at 3-year, with acceptable late toxicities in 45 patients with nasopharyngeal cancer who were received boost radiotherapy, of those 12 patients were treated using the CyberKnife. 12) In that study, a median dose of 12 Gy at 80 -85% isodose line were delivered in a single fraction after a median total dose of 66 Gy by conventional radiotherapy, with an interval of 4-8 weeks. Doses to surrounding normal structures were not fully evaluated. In the present study, for all patients, fractionated SRT boost was utilized. Although a small volume high dose area within the normal structure could be observed in several patients, results of the present study showed potential benefits of the CyberKnife SRT boost. Preceding conventional radiotherapy can deliver prophylactic and/or therapeutic nodal irradiation for cancer in the head and neck region. And the succeeding SRT boost makes it possible to deliver highly conformal fractionated radiotherapy for tumors with unfavorable condition such as close proximity to serial organs or former radiotherapy fields for other malignancies. Using this method, GTV can be irradiated without using large dose per fractionation that is deleterious for risk organs. This study had limitations in that small patient number from heterogenic disease sites with a short follow-up period. In addition, there is a known weakness in the dosimetric analysis where it is still under development to evaluate cumulative dose from different radiotherapy modalities. It is already technically possible to treat multiple nodal metastases simultaneously, however, care should be taken in applying this method until above mentioned dosimetric problem is solved. We now apply SRT boost technique only for N0 or N1 cases. Considering the fact that there were three patients with local progression, dose escalation and/or change in the fractionation schedule in the SRT boost component should be concerned, if doses for risk organs can be acceptable. Thus, it is considered that further studies will be required to sufficiently evaluate efficacy and toxicity of this approach.
